---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-153582"
form_type: "8-K"
ticker: null
cik: "0001693011"
company_name: "Inozyme Pharma, Inc."
filed_at: "2025-07-01T23:59:59+00:00"
generated_at: "2026-05-18T10:05:15.659629+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# BioMarin completes acquisition of Inozyme for $4.00 per share; Inozyme to delist

## Summary
- BioMarin completed tender offer acquiring 69.8% of Inozyme shares at $4.00/share cash; subsequent merger completed July 1, 2025.
- Inozyme will delist from Nasdaq and deregister under Exchange Act; Form 15 to be filed.
- All Inozyme directors resigned; G. Eric Davis, Eric Fleekop, Brian Mueller appointed to board.
- Executive officers resigned; G. Eric Davis became President, Eric Fleekop became Secretary.
- In-the-money stock options and RSUs accelerated and cashed out at $4.00/share.

## SEC filing metadata
- accession: 0001193125-25-153582
- form_type: 8-K
- cik: 0001693011
- company_name: Inozyme Pharma, Inc.
- filed_at: 2025-07-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.02, 2.01, 3.01, 3.03, 5.01, 5.03, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1693011/000119312525153582/0001193125-25-153582-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1693011/000119312525153582/d90696d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-153582
- JSON: https://secwatch.observer/filing/0001193125-25-153582.json
- Plain text: https://secwatch.observer/filing/0001193125-25-153582.txt

## Key facts
- M&A Transactions
  Inozyme Pharma, Inc. completed an acquisition involving BioMarin Pharmaceutical Inc. for not specified in excerpt (closed 2025-07-01).
  - Action: acquisition
  - Counterparty: BioMarin Pharmaceutical Inc.
  - Consideration: not specified in excerpt
  - Closing: 2025-07-01
  source text: On July 1, 2025, BioMarin Pharmaceutical Inc., a Delaware corporation (“ BioMarin ”) completed its acquisition of Inozyme Pharma, Inc., a Delaware corporation (the “ Company ” or “ Inozyme ”) pursuant to an Agreement and Plan of Merger, dated May 16, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1693011/000119312525153582/0001193125-25-153582-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.